Michael Carroll, PhD

Professor of Pediatrics and Pathology, Harvard Medical School
Senior Investigator Immune Disease Institute, Boston

Dr. Carroll received his PhD from the University of Texas Southwestern Medical School in Dallas in 1980 where he studied the biochemistry and genetics of the complement system in the laboratory of Don Capra. He subsequently joined the laboratory of Dr. Rodney Porter in the Department of Biochemistry at Oxford University, UK where he cloned the first human complement gene (complement C4). In 1985, he was recruited to Children’s Hospital and Harvard Medical School in Boston where he now serves as the Senior Investigator at the Immune Disease Institute and Professor of Pediatrics in the Program in Cellular and Molecular Medicine at Children’s Hospital and Harvard Medical School. Dr. Carroll also serves as Director of the Graduate Program in Immunology at Harvard University. He is the author of over 150 peer -reviewed articles and his research currently focuses on how the innate immune system regulates the adaptive response to viral and bacterial infection, autoimmunity and inflammation. 

Francis Moore, MD

Professor of Surgery, Harvard Medical School
Chief, Division of General and Gastrointestinal Surgery, Brigham and Women's Hospital

Dr. Moore holds the Francis D. Moore Chair of Surgery at Harvard. He graduated from Harvard College and Harvard Medical School, with internship and residency in Surgery at the Peter Bent Brigham Hospital and Brigham and Women's Hospital, respectively.  During surgery training, he also completed two years of research training in Immunology with Drs. K. Frank Austen and Douglas Fearon, concentrating on the basic biology of the complement system. Since joining the attending staff in surgery at Brigham and Women's in 1984, he has pursued a vigorous investigational program, as well as developing a busy clinical enterprise of some 20 general surgeons on- and off-site.  He is in his 17th year as P.I. of a P50 Trauma Center grant, funded by NIGMS. His long-term specific research interest has been the autologous inflammatory amplification of injury and the use of that research knowledge to lessen the impact of injury on human patients.